Related Experiment Videos
Therapy evaluation, patient distribution, and cost-outcomes ratios
1Center for Pharmaceutical Economics, College of Pharmacy, University of Arizona, Tucson, USA.
Clinical Therapeutics
|March 1, 1995
Summary
Pharmacoeconomic analysis should shift focus from cost-outcomes ratios. Equilibrium-to-equilibrium modeling provides a robust framework for evaluating drug choices based on expected patient distribution and net changes in costs and outcomes.
Area of Science:
- Health Economics
- Pharmacoeconomics
- Decision Science
Background:
- Current pharmacoeconomic literature often relies on cost-outcomes ratios for drug selection.
- This approach may be flawed without specific assumptions about cost and outcome functions.
Purpose of the Study:
- To critique the overemphasis on cost-outcomes ratios in pharmacoeconomic decision-making.
- To propose an alternative modeling framework for evaluating drug therapies.
Main Methods:
- The paper advocates for an equilibrium-to-equilibrium modeling framework.
- This framework assumes constant returns to scale for cost and outcome functions.
- It analyzes expected shifts in patient distribution across therapies.
Main Results:
- Cost-outcomes ratios are deemed insufficient for robust drug choice evaluation.
- Equilibrium-to-equilibrium modeling allows for estimation of net changes in costs and outcomes.
- This method is valid under the assumption of constant returns to scale.
Conclusions:
- The reliance on cost-outcomes ratios in pharmacoeconomics is misplaced.
- An equilibrium-to-equilibrium modeling approach offers a more rigorous basis for therapeutic option evaluation.
- Accurate assessment requires considering patient distribution and marginal cost-outcome relationships.